Nanosuspensions in drug delivery

Nature Reviews Drug Discovery

Volumn 3, Issue 9, 2004, Pages 785-796

  Rabinow, Barrett E ^a  

^a BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; APREPITANT; BUDESONIDE; BUSULFAN; CALCIUM PHOSPHATE; CLOFAZIMINE; DIAGNOSTIC AGENT; FENOFIBRATE; INSULIN; ITRACONAZOLE; NANOPARTICLE; NAPROXEN; PACLITAXEL; RAPAMYCIN; SILVER;

AREA UNDER THE CURVE; ASTHMA; ATOPIC DERMATITIS; CLINICAL TRIAL; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG RESEARCH; DRUG SOLUBILITY; DRUG STABILITY; ECZEMA; HUMAN; MICROCRYSTALLINE SUSPENSION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; DRUG INDUSTRY; HUMANS; MICROSPHERES; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SUSPENSIONS;

EID: 4544383493     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1494     Document Type: Review

References (114)

1. Na, G. C. et al. Physical stability of ethyl diatrizoate nanocrystalline suspension in steam sterilization. Pharm. Res. 16, 569-574 (1999).
2. Horn, D. & Rieger, J. Organic nanoparticles in the aqueous phase-theory, experiment, and use. Angew. Chem. Int. Ed. 40, 4330-4361 (2001).
3. Muller, R. H. et al. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. and Biopharm. 50. 161-177 (2000).
4. Lipinski, C. A., Lombardo, F., Dominy, B. & Feeney, P. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Reviews 23, 3-25 (1997).
5. Yalkowsky, S. H. Techniques of Solubilization of Drugs 1-14 (Marcel Dekker, New York, 1981).
6. Joshi, A. Microparticulates for ophthalmic drug delivery. J. Ocular Pharm. 10, 29-45 (1994).
7. LeBourlais, C. et al. Ophthalmic drug delivery systems-recent advances. Prog. Retinal and Eye Res. 17, 33-58 (1998).
8. Weiner, M. and Bernstein, I. L. Adverse Reactions to Drug Formulation Agents (Marcel Dekker, New York, 1989).
9. Gad, S. C. Drug Safety Evaluation Ch. 13.8 (John Wiley and Sons, New York, 2002).
10. Ziller, K. H & Rupprecht, H. H. Control of crystal growth in drug suspensions. Part II: influence of polymers on dissolution and crystallization during temperature cycling. Pharm Ind, 52, 1017-1022 (1990).
11. Tabibi, S. E. & Rhodes, C. T. in Modern Pharmaceutics 3rd edn (eds Banker, G. S. & Rhodes C. T.) Ch. 9 (Marcel Dekker, New York, 1996).
12. Myerson, A. S. & Ginde, R. in Handbook of Industrial Crystallization (ed. Myerson, A. S.) 45-46 (Butterworth-Heinemann, Boston, 1992).
13. Garside, J. in Particle Design Via Crystallization (eds Ramanarayanan, R. et al.) 16-25 (AIChE Symposium Series, Vol. 87, New York, 1991).
14. Muller, R. H. & Peters, K. Nanosuspensions for the formulation of poorly water soluble drugs. I. Preparation by a size reduction technique. Int. J. Pharm. 160, 229-237 (1998).
15. Liedtke, S., Wissing, S., Muller, R. H. & Mader, K. Influence of high pressure homogenisation equipment on nanodispersions characteristics. Int. J. Pharm. 196, 183-185 (2000).
16. Pandolfe, W. D. Development of the new Gaulin Micro-Gap™ homogenizing valve. J. Dairy Sci. 65, 2035-2044 (1982).
17. Schultz, S., Wagner, G. & Ulrich, J. On the influence of geometric parameters of a combined orifice valve on the attainable mean droplet diameter during high-pressure homogenization. Eng. Life Sci. 2, 337-340 (2002).
18. Kinney, R. R. et al. Homogenization valve. US Patent 5,749,650 (1998).
19. Wilbey, A. Homogenization. J. Soc Dairy Tech. 45, 31-32 (1992).
20. Jahnke, S. in Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs (eds Muller, R. H., Benita, S. & Bohm, B.) 177-200 (Medpharm Scientific, Stuttgart, 1998).
21. Mohr, K.-H. High-pressure homogenization. Part I. Liquid-liquid dispersion in turbulence fields of high energy density. J. Food Engineer. 6, 177-186 (1987).
22. Pandolfe, W. D. Effect of dispersed and continuous phase viscosity on droplet size of emulsions generated by homogenization. J. Dispersion Sci. Tech. 2, 459-474 (1981).
23. Huttenrauch, R. Fundamentals of pharmaceutics. Acta Pharm. Technol. 34, 1-10 (1988).
24. Grant, D. & York, P. Entropy of processing: a new quantity for comparing the solid state disorder of pharmaceutical materials. Int. J. Pharmaceutics 30, 161-180 (1986).
25. Duddu, S. P. & Grant, D. The use of thermal analysis in the assessment of crystal disruption. Thermochimica Acta. 248, 131-145 (1995)
26. Kipp, J. E. et al. Microprecipitation method for preparing submicron suspensions. US Patent 6,607,784 B2 (2003).
27. Merisko-Liversidge, E., Liversidge, G. G. & Cooper, E. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm Sci. 18, 113-120 (2003).
28. Sarkari, M. et al. Enhanced drug dissolution using evaporative precipitation into aqueous solution. Int. J. Pharm. 243, 17-31 (2002).
29. Peters, K. et al. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J. Antimcrob. Chem. 45, 77-83 (2000).
30. Toguchi, H. Sterility assurance of microspheres. J. Contr. Rel. 62, 51-55 (1999)
31. Zheng, J. Y. & Bosch, J. W. Sterile filtration of NanoCrystal™ drug formulations. Drug Develop. Ind. Pharm. 23, 1087-1093 (1997).
32. Konan, Y. N., Gurny, R. & Allemann, E. Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles. Int. J. Pharm. 233, 239-252 (2002).
33. Na, G. C., Stevens, H. J., Yuan, B. & Rajagopalan, N. Physical stability of ethyl diatrizoate nanocrystalline suspension in steam sterilization. Pharm. Res. 16, 569-574 (1999).
34. Floyd, A. G. & Jain, S. in Pharmaceutical Dosage Forms, Disperse Systems 2nd edn Vol. 2 (eds Lieberman, H. A., Rieger, M. M.. & Banker, G. S.) 295-298 (Marcel Dekker, New York, 1996).
35. Akers, M. J., Fites, A. L. & Robison, R. L. Formulation design and development of parenteral suspensions. J. Parenter. Sci. Tech. 41, 88-96 (1987).
36. Barber, T. A. in Pharmaceutical Particulate Matter: Analysis and Control Ch. 8 (Interpharm, Buffalo Grove, 1993).
37. Weiner, B. B. in Liquid- and Surface-Borne Particle Measurement Handbook (eds Knapp, J. Z., Barber, T. A. & Lieberman, A Ch. 5 (Marcel Dekker, New York, 1996).
38. Lines, R. W. in Liquid- and Surface-Borne Particle Measurement Handbook (eds Knapp, J. Z., Barber, T. A. & Lieberman, A Ch. 4 (Marcel Dekker, New York, 1996).
39. <788> Particulate Matter in Injections, Microscopic Particle Count Test. USP 27 The United States Pharmacopeia, United States Pharmacopeial Convention Inc. Rockville, Md. (2004).
40. Shi, H. G. et al. Characterization of crystalline drug nanoparticles using atomic force microscopy and complementary techniques. Pharm. Res. 20, 479-484 (2003).
41. Kuentz, M. and Rothlisberger, D. Rapid assessment of sedimentation stability in dispersions using near infrared transmission measurements during centrifugation and oscillatory rheology. Eur. J. Pharm. Biopharm. 56, 355-361 (2003).
42. Giron, D. Thermal analysis and calorimetric methods in the characterisation of polymorphs and solvates. Thermochim. Acta 248, 1-59 (1995).
43. Yoshii, K. Application of differential scanning calorimetry to the estimation of drug purity: various problems and their solutions in purity analysis. Chem. Pharm. Bull. 45, 338-343 (1997).
44. Barnes, A. F. et al. A review of the applications of thermal methods within the pharmaceutical industry. J. Thermal Anal. 40, 499-509 (1993).
45. Higgins, J. P. Spectroscopic approach for on-line monitoring of particle size during the processing of pharmaceutical nanoparticles. Anal. Chem. 75, 1777-1785 (2003).
46. Nicolaides, E. et al. Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration. Pharm. Res. 18, 380-388 (2001).
47. Dressman, J. B. & Reppas, C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Euro. J. Pharm. Sci. 11 (Suppl. 2), S73-S80 (2000).
48. U. S. Dept. of Health and Human Services, Food and Drug Administration. Guidance for Industry: Liposome Drug Products; Chemistry, manufacturing, and controls; human pharmacokinetics and bioavailability; and labeling documentation, August 2002.
49. Donovan, M. & Flanagan, D. in Pharmaceutical Dosage Forms, Disperse Systems 2nd edn Vol. 2. (eds Lieberman, H. A., Rieger, M. M. & Banker, G. S.) Ch. 8 (Marcel Dekker. New York, 1996).
50. Jia, L., Wong, J., Cerna, C. & Weitman, S. Effect of nanonization on absorption of 301029: ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography/mass spectrometry. Pharm. Res. 19, 1091-1096(2002).
51. Liversidge, G. & Cundy, K. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int. J. Pharm. 125, 91-97 (1995).
52. Liversidge, G. G. & Conzentino, P. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int. J. Pharm. 125, 309-313 (1995).
53. Tong, W-Q. in Water-Insoluble Drug Formulation (ed. Liu, R.) Ch. 4 (Interpharm, Denver, 2000).
54. Desai, M. P. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res. 13, 1838-1845 (1996).
55. Duchene, D. & Ponchel, G. Bioadhesion of solid oral dosage forms, why and how? Eur. J. Pharm. and Biopharm. 44, 15-23 (1997).
56. Behrens, I., Pena, A. I, Alonso, M. J. & Kissel, T. Comparative uptake studies of bioadhesive and nonbioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport. Pharm. Res. 19, 1185-1193 (2002).
57. Florence, A. T. & Hussain, N. Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. Adv. Drug Del. Rev. 50, S69-S89 (2001).
58. Lamprecht, A., Schafer, U. & Lehr, C-M. Size dependent bioadhesion of micro-and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res. 18, 788-794 (2001).
59. Florence, A. T. & Hussain, N. Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. Adv. Drug Del. Rev. 50, S69-S89 (2001).
60. Jani, P., Halbert, G., Langridge, J. & Florence, A. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J. Pharm. Pharmacol. 42, 821-826 (1990).
61. Clark, M., Jepson, M. & Hirst, B. Exploiting M cells for drug and vaccine delivery. Adv. Drug Deliv. Rev. 50, 81-106 (2001).
62. O'Driscoll, C. M. in Lymphatic Transport of Drugs (eds Charman, W. N. & Stella, V. J.) 1-35 (CRC, Florida, 1992).
63. 12-mediated transport of nanoparticles across Caco-2 cells. Int. J. Pharm. 179, 247-255 (1999).
64. Bittner, B. & Mountfield, R. J., Intravenous administration of poorly soluble new drug entities in early durg discovery: the potential impact of formulatin on pharmacokinetic parameters. Curr. Opinion Drug Discov. Dev. 5, 59-71 (2002).
65. Theis, J. G. et al. Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance:the causative role of improper dissolution of cremophor EL. J. Clin. Oncol. 13, 2508-2516 (1995).
66. O'Dwyer, P. J. & Weiss, R. B. Hypersensitivity reactions induced by etoposide. Cancer Res. 68, 959-961 (1984).
67. Duma, R. J., Akers, M. J. & Turco, S. J. in Pharmaceutical Dosage Forms: Parenteral Medications 2nd edn Vol. 1 (eds Avis, K. E., Lieberman, H. A. & Lachman, L.) 17-58 (Marcel Dekker, New York, 1992 ).
68. Ward, G. H. & Yalkowsky, S. H. Studies in Phlebitis. VI. Dilution-induced precipitation of amiodarone HCI. J. Parenter. Sci. Technol. 47, 161-165 (1993).
69. Davio, S. R. et al. Precipitation of the renin inhibitor ditekiren upon iv infusion; in vitro studies and their relationship to in vivo precipitation in the cynomolgus monkey. Pharm. Res. 8, 80-83 (1991).
70. Davis, S. S. et al. Lipid emulsions as drug delivery systems. Ann. NY Acad. Sci. 507, 76-78 (1987b).
71. Yalkowsky, S. H. Techniques of Solubilization of Drugs 1-14 (Marcel Dekker, New York, 1981).
72. Merisko-Liversidge, E. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm. Res. 13, 272-278 (1996).
73. Boedeker, B. H., Logeski, E., Kline, M. & Haynes, D. Ultra-long duration local anesthesia produced by injection of lecithin-coated tetracaine microcrystals. J. Clin Pharmacol. 34, 699-702 (1994).
74. Karan, S. M. et al. Intravenous lecithin-coated microcrystals of dantrolene are effective in the treatment of malignant hyperthermia:an investigation in rats, dogs, and swine. Anesth. Analg. 82, 796-802 (1996).
75. Shulman, M. Treatment of cancer pain with epidural butylamino benzoate suspension. Reg. Anesth. 12, 1-4 (1987).
76. Clement, M. A. et al. Tissue distribution and plasma clearance of a novel microcrystal-encapsulated flurbiprofen formulation. The Pharmacologist 34, 204 (1992).
77. Gassmann, P. et al. Hydrosols: Alternatives for the parenteral application of poorly water soluble drugs. Eur. J. Pharm. Biopharm. 40, 64-72 (1994).
78. Viernstein, J. & Stumpf, C. Similar central actions of intravenous methohexitone suspension and solution in the rabbit. J. Pharm. Pharmacol. 44, 66-68 (1992).
79. Parikh, I. et al. Microcrystal technology-based sustained delivery of nifedipine in rats. The Pharmacologist 33, 197 (1991).
80. Zuidema, J., Pieters. F. A. & Duchateau, G. Release and absorption rate aspects of intramuscularly injected pharmaceuticals. Int. J. Pharm. 47, 1-12 (1988).
81. Stout, P. J. M. et al. Dissolution performance related to particle size distribution for commercially available prednisolone acetate suspensions. Drug Development Ind. Pharm. 18, 395-408 (1992).
82. Moghimi, S. M., Hunter, A. C. & Murray, J. C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53, 283-318 (2001).
83. Mukherjee, S., Ghosh, R. N. & Maxfield, F. R. Endocytosis. Physiol. Rev. 77, 759-803 (1997).
84. Andes, D. et al. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis, Antimicrob. Agents Chemother. 47, 1179-1186 (2003).
85. Rabinow, B. E. et al. Enhanced efficacy of NANOEDGE itraconazole nanosuspension in an immunosuppressed rat model infected with an itraconazole-resistant C. albicans strain. Am. Assoc. Pharma. Scientists AR6184 (2003).
86. Donnelly, J. P. et al. Pharmacokinetics of a 14 day course of itraconazole nanocrystals given intravenously to allogeneic haematopoietic stem cell transplant (HCST) recipients. 41st Intersci. Conf. Antimicrob. Agents Chemother. A32 (2001).
87. Sporanox (Itraconazole) injection: approved labeling. Physicians' Desk Reference 1772-1776 (Thomson PDR, Montvale, 2004).
88. Willems, L., van der Geest, R. & de Beule, K. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J. Clin. Pharm. Ther. 26, 159-169 (2001).
89. McIntire, G. L. et al. Time course of nodal enhancement with CT X-ray nanoparticle contrast agents: effect of particle size and chemical structure. Investigative Radiol. 35, 91-96 (2000).
90. Onyuksel, H. & Rubinstein, I. Materials and methods for making improved micelle compositions; lipid bonded to water soluble polymer. US Patent 6,217,886 (2001).
91. Wu, N. et al. Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue. Cancer Res. 53, 3765-3770 (1993).
92. 14C-Poly (methylmethacrylate) nanparticles in experimental tumor models. Pharm. Res. 18, 1613-1619 (2001).
93. Martonen, T. B. & Katz, I. M. Deposition patterns of aerosolized drugs within the human lungs. Pharm. Res. 10, 871-878 (1993).
94. Chan, H.-K. & Gonda, I. Development of a systematic theory of suspension inhalation aerosols. II. Aggregates of monodisperse particles nebulized in polydisperse droplets. Int. J. Pharm. 41, 147-157 (1988).
95. Wiedmann, T. S., DeCastro, L. & Wood, R. W. Nebulization of NanoCrystals™: Production of a respirable solid-in-liquid-in-air colloidal dispersion. Pharm. Res. 14, 112-116 (1997).
96. Ostrander, K. D., Bosch, H. & Bondanza, D. An in vitro assessment of a NanoCrystal™ beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization. Eur. J. Pharm. and Biopharm. 48, 207-215 (1999).
97. Keller, M., Jauernig, J., Lintz, F-C. & Knoch, M. Nebulizer nanosuspensions: important device and formulation interactions. Resp. Drug Delivery VIII, 197-206 (2002).
98. Jacobs, C. & Muller, R. H. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm. Res. 19, 189-194 (2002).
99. Dailey, L. A. et al. Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. J. Control. Rel. 86, 131-144 (2003).
100. Kraft, W. K. et al. The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers. J. Clin. Pharmacol. 44, 67-72 (2004).
101. Sharma, R., Saxena, D., Dwivedi, A. & Misra, A. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm. Res. 18, 1405-1410 (2001).
102. Vyas, S. P., Kannan, M., Jain, S., Mishra, V. & Singh, P. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int. J. Pharm. 269, 37-49 (2004).
103. Foster, K. A., Yazdanian, M. & Audus, K. Microparticulate uptake mechanims of in-vitro cell culture models of the respiratory epithelium. J. Pharm. Pharmacol. 53, 57-66 (2001).
104. Edwards, D. A. Large porous particles for pulmonary drug delivery. Science 276, 1868-1871 (1997).
105. Evora, C. et al. Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine. J. Contr. Rel. 51, 143-152 (1998).
106. Tsapis, N., Bennett, D., Jackson, B., Weitz, D. & Edwards, D. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc. Natl Acad. Sci. USA. 99, 12001-12005 (2002).
107. Grossman, S. A. & Krabak, M. J. Leptomeningeal carcinomatosis. Cancer treatment reviews 25, 103-119 (1999).
108. Archer, G. E. et al. Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats. J. Neuro-Oncology. 44, 233-241 (1999).
109. Shulman, M., Hoseph, N. J. & Haller, C. A. Effect of epidural and subarachnoid injections of a 10% butamben suspension. Reg. Anesth. 15, 142-146 (1990).
110. Koukourakis, M. et al. High intratumoural accumulation of stealth® liposomal doxorubicin (Caelyx®) in glioblastomas and in metastatic brain tumours. Brit. J. Cancer 83, 1281-1286 (2000).
111. Kreuter, J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Reviews 47, 65-81 (2001).
112. Gessner, A., Olbrich, C., Schroder, W., Kayser, O. & Muller, R. H. The role of plasma proteins in brain targeting: species dependent protein adsorption patterns on brain-specific lipid drug conjugate (LDC) nanoparticles. Int. J. Pharm. 214, 87-91 (2001).
113. Schroder, U. & Sabel, B. A. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections. Brain Res. 710, 121-124 (1996).
114. Vanderhoff, J. W. in Pharmaceutical Dosage Forms, Disperse Systems 2nd edn Vol. 2 (Lieberman, H. A., Rieger, M. M. & Banker, G. S.) Ch. 4 (Marcel Dekker, New York, 1996).